Piper Sandler Initiates Coverage On Sarepta Therapeutics with Overweight Rating, Announces Price Target of $157
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has initiated coverage on Sarepta Therapeutics with an Overweight rating and a price target of $157.
May 31, 2024 | 10:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has initiated coverage on Sarepta Therapeutics with an Overweight rating and a price target of $157. This positive analyst rating could boost investor confidence and potentially drive the stock price up in the short term.
The initiation of coverage with an Overweight rating and a high price target by a reputable analyst can positively influence investor sentiment and lead to a short-term increase in the stock price of Sarepta Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100